FDA Center for Drug Evaluation & Research Issues Warning Letter to Respilon Production S.R.O.
May 06, 2026
May 06, 2026
WASHINGTON, May 6 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Respilon Production S.R.O. from its Center for Drug Evaluation and Research:
* * *
Recipient: Mr. Roman Zima, Chief Executive Officer, Respilon Production S.R.O., Prikop 843/4 Brno, 602 00 Jihomoravsky, Czechia
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
Warning Letter 320-26 . . .
* * *
Recipient: Mr. Roman Zima, Chief Executive Officer, Respilon Production S.R.O., Prikop 843/4 Brno, 602 00 Jihomoravsky, Czechia
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
Warning Letter 320-26 . . .